Tracking Treatment Effectiveness: A 6-Domain Framework for Patients and Providers

Determining "Is this treatment working?" requires more than a symptom checklist. Effective evaluation integrates clinical data, functional status, objective biomarkers, patient-reported outcomes, and the therapeutic alliance across a structured timeline. This framework empowers patients to be active partners in monitoring their care.

The 6-Domain Evaluation Framework

1. Clinical Symptom Trajectory

  • Frequency/Intensity/Duration: Standardized scales (PHQ-9, GAD-7, PCL-5, Y-BOCS, PANSS, AIMS, DAS28, seizure diary, pain NRS).
  • Goal Attainment Scaling (GAS): Individualized, weighted goals (-2 to +2) — more sensitive than population norms.
  • Pattern Recognition: Cyclical? Trigger-linked? Time-of-day? Weekend vs. weekday?

2. Functional Status & Participation

  • WHO Disability Assessment Schedule (WHODAS 2.0) or Sheehan Disability Scale (SDS): Work/school, social, family, self-care domains.
  • Activity-Specific: "Can I play with my kids?" "Can I finish a shift?" "Can I drive?"
  • Physical Performance: 6-min walk test, grip strength, TUG (Timed Up & Go), ROM, MMT — for MSK/neuro conditions.

3. Objective Biomarkers & Diagnostics

  • Laboratory: HbA1c, lipids, LFTs, renal, inflammatory markers (CRP, ESR), drug levels (lithium, valproate, clozapine, antiretrovirals).
  • Imaging: Tumor response (RECIST), MRI lesion load (MS), echocardiogram (EF), DEXA (bone density).
  • Physiologic: HRV, actigraphy (sleep), CGM (glucose), spirometry.

4. Self-Monitoring Tools & Digital Phenotyping

  • Structured Journals: Paper or apps (Daylio, Bearable, Symple, Condition-specific: AsthmaMD, MyFitnessPal, Clue).
  • Wearables: HRV, sleep stages, activity, SpO2, ECG, temperature trends — contextualized by clinician.
  • Ecological Momentary Assessment (EMA): Real-time prompts → reduces recall bias.

5. Therapeutic Alliance & Provider Engagement

  • Visit Frequency & Quality: Shared agenda setting, measurement-based care (MBC) — reviewing scales *together*.
  • Medication Adherence: MPR (Medication Possession Ratio), self-report (Morisky), pharmacy fills, long-acting injectables (LAIs).
  • Specialist Communication: Interoperable notes, e-consults, tumor boards, case conferences.

6. Quality of Life & Existential Domains

  • Validated QoL: SF-36/12, EQ-5D, WHOQOL-BREF, FACT-G (cancer), MSQOL-54.
  • Subjective Well-Being: Flourishing scale, meaning/purpose (Ryff), hope (Snyder).
  • Relationship & Role Satisfaction: "Am I the parent/partner/employee I want to be?"

Operationalizing the Framework

  1. Baseline (Pre-Tx): Capture all 6 domains.
  2. Early Phase (Weeks 2-8): Focus: Safety, tolerability, engagement, early symptom shift (Domain 1, 5).
  3. Acute Phase (Months 2-6): Focus: Symptom reduction, functional gains (Domain 1, 2, 3).
  4. Maintenance (6mo+): Focus: Relapse prevention, QoL, de-escalation if stable (Domain 4, 6).
  5. Decision Points: Pre-defined criteria for: continue, augment, switch, taper, refer.

Patient Empowerment Checklist

  • Bring your data (app export, journal, home BP/glucose logs) to every visit.
  • Ask: "What does response look like for *me* at 4 weeks? 12 weeks?"
  • Request Measurement-Based Care: "Can we review my PHQ-9 trend today?"
  • Voice side effects *and* functional wins.
  • If provider dismisses your tracking → find one who values it.

Treatment is a hypothesis. Data—yours and your clinician's—tests it. Rigorous, collaborative monitoring turns hope into evidence.

Illness - Related Articles